<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2808">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04343404</url>
  </required_header>
  <id_info>
    <org_study_id>7772</org_study_id>
    <nct_id>NCT04343404</nct_id>
  </id_info>
  <brief_title>Place of ECMO in the Management of Severe Refractory ARDS Associated With Covid-19</brief_title>
  <acronym>ECMO-COVID-19</acronym>
  <official_title>STUDY ECMO-COVID-19 : Place of ECMO in the Management of Severe Refractory ARDS Associated With Covid-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Describe COVID-19 patients who are receiving ECMO-VV respiratory replacement and what happens
      to them.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Actual">April 15, 2020</completion_date>
  <primary_completion_date type="Actual">April 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Retrospective description of COVID-19 patients receiving respiratory ECMO-VV supplementation and what happens to them</measure>
    <time_frame>Files analysed retrospectily from March 1st, 2020 to April 15, 2020 will be examined</time_frame>
  </primary_outcome>
  <enrollment type="Actual">100</enrollment>
  <condition>Respiratory Distress Syndrome</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with a COVID-19 diagnosis by RT-PCR
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient over the age of 18;

          -  Diagnostic COVID-19 by RT-PCR;

          -  Hospitalisation in resuscitation for the management of complications related to
             COVID-19

          -  Implanted ECMO-VV during hospitalisation;

          -  Patient agreeing to participate in the study

        Exclusion Criteria:

          -  Sujet under guardianship or trusteeship

          -  Sujet under safeguard of justice
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Pierre-Emmanuel FALCOZ, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Service de Chirurgie Thoracique Nouvel H么pital Civl H么pitaux Univesitaires de Strasbourg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de Chirurgie Thoracique Nouvel H么pital Civil H么pitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 8, 2020</study_first_submitted>
  <study_first_submitted_qc>April 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>June 25, 2020</last_update_submitted>
  <last_update_submitted_qc>June 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Respiratory Distress Syndrome</keyword>
  <keyword>ARDS</keyword>
  <keyword>SARS-COV-2</keyword>
  <keyword>Extracorporeal membrane oxygenation</keyword>
  <keyword>ECMO</keyword>
  <keyword>Veno-venous ECMO</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

